185 results about "Epinephrine synthesis" patented technology

A method of administering epinephrine to a patient includes administering a first dose by automatic injection followed by administering a second dose by manual injection. The first and second injections are administered using the same syringe. In some embodiments, the first and second injections provide the same volume of medicine to the patient. In particular embodiments, the first and second injections have volumes of 0.15 or 0.3 ml.

A method of administering liquid medicine such as epinephrine to a patient includes administering a first dose followed by administering an optional second dose is described herein. Also described herein are devices useful for carrying out the methods described and kits containing these devices.

The present invention relates to methods for administering a first dose of epinephrine solution and an optional second dose of epinephrine solution. Also provided herein are kits useful in these methods.

Highly shelf-stable electrically assisted transdermal drug delivery systems for delivering epinephrine, typically with an anesthetic such as lidocaine, are provided along with methods for making the highly shelf-stable epinephrine-containing transdermal delivery device. Highly shelf-stable packaged electrode assemblies for transdermal delivery of epinephrine also are provided.

This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.

Described herein are formulations for fast-disintegrating epinephrine tablets which can be prepared for buccal or sublingual administration, wherein the fast-disintegrating epinephrine tablets can produce plasma epinephrine concentrations similar to those achieved by an approximately 0.3 mg epinephrine dose in the thigh (Epi-Pen).

The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.

Compositions and methods are provided for obtaining stabilized quinol compositions, such as catecholamine drugs (e.g., epinephrine solutions), and also for obtaining stable pharmaceutical formulations that comprise a stabilized quinol composition and a second pharmacologically active component such as a local anesthetic or other active drug ingredient having a reversibly protonated amine group. Stability is achieved through the inclusion of an appropriately selected pH buffer and a thiol agent, based on redox and pH buffering principles including pKa of the buffer and of the reversibly protonated amine group.

A preparation used for iontophoresis in order to absorb a physiologically active substance via the skin or mucosa using electrical driving force and the preparation containing a local anesthetic, epinephrine or its salt, water and chlorobutanol.

Disclosed herein are compositions comprising an amide related to a prostaglandin and an amine wherein the amine is selected from the group consisting of epinephrine, dopamine, serotonin, and analogs or prodrugs thereof. Also disclosed are certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.

The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.

Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

Guanosine triphosphate pathway tetrahydrobiopterin synthesis antagonist and/or pterin salvage pathway tetrahydrobiopterin synthesis antagonists are administered to inhibit nitric oxide synthesis from arginine in vascular cells in a subject in need of such inhibition (e.g., for prophylactic or curative effect for endotoxin- or cytokine-induced hypotension or for restoration of vascular contractile sensitivity to pressor agents in the treatment of such hypotension). The tetrahydrobiopterin synthesis antagonist may be administered with alpha 1-adrenergic agonist or with nitric oxide synthase inhibitor. The tetrahydrobiopterin synthesis antagonists are also administered to attenuate inflammation caused by induced nitric oxide production in immune cells. Unwanted counterproductive or side effects can be eliminated or ameliorated by administration additionally of levodopa with or without carbidopa and L-5-hydroxytryptophane.

A near-permanent skin treatment includes photothermolysis of reddened facial skin to induce ischemia. Reperfusion of the photothermolysis treated skin is inhibited by following with regular applications of phenyl-epinephrine carried in a lotion until vascular necrosis is complete. Alternatively, a temporary treatment for reddened facial skin includes only cosmetic as-needed applications of phenyl-epinephrine carried in lotion to induce vasoconstriction in Rosacea and other similarly embarrassing skin disorders.

The present invention describes novel nitrosated and/or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated α-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one α-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

The instant invention is directed towards an intra-operative method and kit for essentially eliminating pain associated with and resulting from surgical procedures, comprising the administration of a medical solution including a mixture of an injectable anesthetic, epinephrine, sodium chloride and an injectable anti-inflammatory agent to a plurality of sites within a surgical field utilizing a means for administration which, in a contemplated embodiment, may include a hollow shaft having a proximal end and a distal end, wherein upon administration, said medical solution flows within said shaft from said proximal end toward said distal end, which distal end is defined by a solid end having a plurality of circumferentially positioned apertures in said shaft for providing radially directed flow of the medicated solution circumferentially about said shaft.

The present invention relates to methods of administering dosage forms which comprise epinephrine, including buccal, lingual, sublingual or transmucosal dosage forms comprising epinephrine for treatment of allergic emergencies, including anaphylaxis. Also provided herein are kits and packaging systems useful in these methods.

An apparatus for providing therapeutically effective mixtures of buffered lidocaine (with and without epinephrine) while simultaneously increasing the shelf life, having a two-chambered medicine vial, in which one chamber isolates up to 20 ml of a lidocaine solution (1% with or without epinephrine) and the other chamber isolates up to 2 ml of sodium bicarbonate (8.4%), with a fracturable wall therebetween such that the wall is fractured by bending or twisting, for mixing the lidocaine and sodium bicarbonate to create a buffered lidocaine for administration in therapeutically effective amounts, and further comprising stopper means, like a rubber stopper, for the insertion of a syringe for extraction of the mixture for administration. Also shown is a method for isolating the components for shelf life and providing mixing for an effective composition.

This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.

A stable suspension aerosol formulation of epinephrine is suitable for administration through inhalation comprising a therapeutically effective amount of epinephrine, hydrofluorocarbon propellant, co-solvent, surfactant, and antioxidant. The suspension aerosol formulation further comprises [pre-] pre-micronized epinephrine suspended in an alcohol/surfactant solution with hydrofluoroalkane propellant. The suspension formulation provides a highly efficient delivery of drug microparticles into the respirable region of patients' lungs and has the following advantages: lower dosage requirement, minimum alcohol content, with less impurities generated during storage, improved efficacy and safety, and exhibits no ozone depleting potential compared to a formulation containing chlorofluorocarbon.